ReviewJournal of molecular neuroscience : MN2003
Antioxidant treatment in Alzheimer's disease: current state.
Review in Journal of molecular neuroscience : MN, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 126 citations in OpenAlex.
- Examining the role of antioxidant supplementation in mitigating oxidative stress markers in Alzheimer's disease: a comprehensive review.Inflammopharmacology · 2025Review
- Components in SLPE Alleviate AD Model Nematodes by Up-Regulating GeneInternational journal of molecular sciences · 2024Article
- Metabolic profiling of Vitex Pubescens Vahl bark via UPLC-ESI-QTOF/MS/MS analysis and evaluation of its antioxidant and acetylcholinesterase inhibitory activities.BMC complementary medicine and therapies · 2024Article
- Green approach for the recovery of secondary metabolites from the roots ofFrontiers in plant science · 2022Article
- WIN55,212-2 Attenuates Cognitive Impairments in AlClBiomedicines · 2021Article
- Stereoselective Synthesis of Selenium-Containing Glycoconjugates via the Mitsunobu Reaction.Molecules (Basel, Switzerland) · 2021Article
- Ellagic Acid Inhibits Neuroinflammation and Cognitive Impairment Induced by Lipopolysaccharides.Neurochemical research · 2020Article
- Therapeutic Application of Betalains: A Review.Plants (Basel, Switzerland) · 2020Review
- Betanin Attenuates Oxidative Stress Induced by 6-OHDA in PC12 Cells via SAPK/JNK and PI3 K Pathways.Neurochemical research · 2020Article
- Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease.Frontiers in pharmacology · 2020Review
- A superoxide scavenging coating for improving tissue response to neural implants.Acta biomaterialia · 2019Article
- Protective Effects ofToxics · 2019Article
- Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1.Oxidative medicine and cellular longevity · 2018Review
- Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Erythrocytes as Potential Link between Diabetes and Alzheimer's Disease.Frontiers in aging neuroscience · 2017Review
- The therapeutic protection of a living and dead Lactobacillus strain against aluminum-induced brain and liver injuries in C57BL/6 mice.PloS one · 2017Article
- Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2016Article
- Possible Mechanisms Involved in Attenuation of Lipopolysaccharide-Induced Memory Deficits by Methyl Jasmonate in Mice.Neurochemical research · 2016Article
- The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state.Nutrition journal · 2016Review
- A simple and convenient method for the preparation of antioxidant peptides from walnut (Juglans regia L.) protein hydrolysates.Chemistry Central journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating data from experimental and human studies indicate that oxidative stress (OS) plays a major role in the pathogenesis of Alzheimer's disease (AD). The production of reactive oxygen species (ROS), which leads to OS, can occur very early, even before the appearance of symptoms and molecular events (beta-amyloid plaques and neurofibrillary tangles), leading to tissue damage via several different cellular molecular pathways. ROS can cause damage to cardinal cellular components such as lipids, proteins, and nucleic acids (e.g., RNA, DNA), causing cell death by modes of necrosis or apoptosis. The damage can become more widespread because of the weakened cellular antioxidant defense systems. Therefore, treatment with antioxidants might theoretically act to prevent propagation of tissue damage and improve both survival and neurological outcome. Indeed, several studies preformed to date examined whether dietary intake of several antioxidants, mainly vitamins, might prevent or reduce the progression of AD. Although a few of the antioxidants showed some efficacy in these trials, no answer is yet available as to whether antioxidants are truly protective against AD. Reasons for these results might include, in part, blood-brain barrier (BBB) permeability, inappropriate timing of administration, or suboptimal drug levels at the target site in the central nervous system. Thus, antioxidant cocktails or antioxidants combined with other drugs may have more successful synergistic effects. Further, well-designed intervention, as well as observational investigations based on large cohorts studied over a long period of time with several methods for assessing antioxidant exposure, including relation to BBB penetration, are needed to test this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.